Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
Status:
Withdrawn
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This is a Phase II treatment study that is done to evaluate how effective and safe the
combination of pembrolizumab and cisplatin work in treating participants with triple-negative
breast cancer that had spread to other parts of the body, has come back, or cannot be removed
by surgery. Pembrolizumab (investigational drug) is a monoclonal antibody that works by
helping your immune system to fight cancer. Cisplatin is a chemotherapy drug that works by
interfering with tumor cell division. Studies also suggest that treatment with chemotherapy,
like cisplatin, may improve the effectiveness of pembrolizumab. This study will test the
effectiveness of pembrolizumab and cisplatin in participants with advanced triple-negative
breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Cisplatin Immunoglobulin G Immunoglobulins Pembrolizumab